ArticleProbiotics and antimicrobial proteins2026
Probiotic Apilactobacillus Kunkeei EABW06 from Beeswax Microbiota: A Candidate for Functional Dairy Foods.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supplementation of Yoghurt withNutrients · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apilactobacillus kunkeei, a fructophilic lactic acid bacterium (FLAB) associated with the honeybee microbiota, has recently gained attention as an unconventional probiotic source. This study evaluated the probiotic, safety, and technological properties of A. kunkeei EABW06, isolated from beeswax, to assess its potential for human and biotechnological applications. A. kunkeei EABW06 demonstrated gastrointestinal resilience, with > 96% survival at pH 3.0 and tolerance to 0.3-0.7% bile salts. It exhibited broad-spectrum antimicrobial activity against Escherichia coli O157:H7, Salmonella typhi, and Clostridioides difficile. Additionally, A. kunkeei EABW06 inhibited fungal pathogens including Aspergillus fumigatus, Aspergillus flavus, and Candida albicans. HPLC analysis revealed acetic, lactic, butyric, and propionic acids as dominant metabolites, correlating with its antimicrobial effects. Safety assessments confirmed no hemolysis, non-cytotoxicity to Caco-2 cells, and sensitivity to clinically relevant antibiotics. In milk fermentation trials, A. kunkeei EABW06 reduced pH to 4.5 ± 0.1, produced 0.98 ± 0.03% lactic acid (titratable acidity), and exhibited proteolytic activity (0.384 ± 0.002) measured by spectrophotometric quantification. In conclusion, A. kunkeei EABW06 is a safe, robust probiotic candidate with potential applications in biopreservation and dairy biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.